Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			2. Issuer Name and Ticker or Trading Symbol <u>QUAKER CHEMICAL CORP</u> [KWR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
·			·	X Officer (give title Other (specify below) below)
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	,
OUNKER	CHEMICAL COR	DOD ATION	11/16/2020	SVP, Managing Director - EMEA
ONE QUA	KER PARK, 901 I	E. HECTOR STREET		
,			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable
(Street)				Line)
l` '	IOCKEN DA	10429		X Form filed by One Reporting Person
CONSHOP	IOCKEN PA	19428		Form filed by More than One Reporting
			"	Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	11/16/2020		М		1,228	A	\$151.75	7,703	D		
Common Stock	11/16/2020		S		91	D	\$251.83(1)	7,612	D		
Common Stock	11/16/2020		S		144	D	\$253.08(2)	7,468	D		
Common Stock	11/16/2020		S		76	D	\$254.14(3)	7,392	D		
Common Stock	11/16/2020		S		240	D	\$ 255.53 ⁽⁴⁾	7,152	D		
Common Stock	11/16/2020	ĺ	S		282	D	\$256.7 ⁽⁵⁾	6,870	D		
Common Stock	11/16/2020		S		368	D	\$257.65(6)	6,502	D		
Common Stock	11/16/2020		S		27	D	\$258.94	6,475	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(13) [11] [12] [12] [12] [12] [12] [12] [12]														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$151.75	11/16/2020		М			1,228	(7)	02/26/2025	Common Stock	1,228	\$0.00	613	D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$251.44 to \$252.03, inclusive. The reporting person undertakes to provide to Quaker Chemical Corporation, d/b/a "Quaker Houghton", any security holder of Quaker Houghton, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$252.58 to \$253.47, inclusive. The reporting person undertakes to provide to Quaker Chemical Corporation, d/b/a "Quaker Houghton", any security holder of Quaker Houghton, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$253.72 to \$254.96, inclusive. The reporting person undertakes to provide to Quaker Chemical Corporation, d/b/a "Quaker Houghton", any security holder of Quaker Houghton, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$255.13 to \$255.99, inclusive. The reporting person undertakes to provide to Quaker Chemical Corporation, d/b/a "Quaker Houghton", any security holder of Quaker Houghton, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$256.20 to \$257.14, inclusive. The reporting person undertakes to provide to Quaker Chemical Corporation, d/b/a "Quaker Houghton", any security holder of Quaker Houghton, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$257.26 to \$258.22, inclusive. The reporting person undertakes to provide to Quaker Chemical Corporation, d/b/a "Quaker Houghton", any security holder of Quaker Houghton, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

7. The options for this grant vest in three annual installments: 614 shares on February 26, 2019; 614 shares on February 26, 2020; and 613 shares on February 26, 2021.

Remarks:

 Victoria K. Gehris, Attorneyin-Fact for Adrian Steeples
 11

 ** Signature of Reporting Person
 Data

11/18/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.